COGT vs. YMAB, SLN, EOLS, IRON, BCYC, PHAR, SVRA, AVTE, PRAX, and DNTH
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Y-mAbs Therapeutics (YMAB), Silence Therapeutics (SLN), Evolus (EOLS), Disc Medicine (IRON), Bicycle Therapeutics (BCYC), Pharming Group (PHAR), Savara (SVRA), Aerovate Therapeutics (AVTE), Praxis Precision Medicines (PRAX), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical preparations" industry.
Y-mAbs Therapeutics (NASDAQ:YMAB) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Y-mAbs Therapeutics has higher revenue and earnings than Cogent Biosciences. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.
Cogent Biosciences has a net margin of 0.00% compared to Cogent Biosciences' net margin of -25.26%. Cogent Biosciences' return on equity of -20.72% beat Y-mAbs Therapeutics' return on equity.
Y-mAbs Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
Cogent Biosciences received 154 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 70.65% of users gave Cogent Biosciences an outperform vote while only 60.51% of users gave Y-mAbs Therapeutics an outperform vote.
In the previous week, Y-mAbs Therapeutics had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 3 mentions for Y-mAbs Therapeutics and 2 mentions for Cogent Biosciences. Y-mAbs Therapeutics' average media sentiment score of 1.26 beat Cogent Biosciences' score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.
Y-mAbs Therapeutics currently has a consensus price target of $16.57, suggesting a potential downside of 3.37%. Cogent Biosciences has a consensus price target of $13.67, suggesting a potential upside of 81.50%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Y-mAbs Therapeutics.
70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 21.5% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Cogent Biosciences beats Y-mAbs Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
